Please login to the form below

Not currently logged in
Email:
Password:

Pfizer looks to expand R&D presence in Asia

Pfizer says it will expand its R&D activities in Asia, specifically China, India, Japan, and South Korea

US-based Pfizer has said that it will expand its R&D activities in Asia, specifically China, India, Japan, and South Korea, according to a Reuter's report.

The company's president of global R&D, Martin Mackay, revealed in the report that Asia was key to the company because its pharmaceutical market would grow to USD 200bn by 2017. He gave no further details of the expansion plans, but added that he was happy with the progress made by Pfizer's two-year old Shanghai R&D centre.

Pfizer says its ranked first in Asia pharmaceutical market sales for the 12 months to June 2007. The company has a manufacturing plant in the Chinese city of Dalian and has research collaborations with Peking University and Tsinghua University. It opened a research centre in Shanghai in 2005 and says it wants to expand clinical research activities globally, with nearly 80 studies ongoing.

Mackay told Reuters at an investors' meeting: "China is going to be really important to us; the Shanghai centre is going to be exceptionally important. We are looking at Korea, India and other countries."

The world's largest pharmaceutical company recently announced a USD 300m R&D investment in South Korea over the next five years to develop drugs and medical technology.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics